Index Options
State Street
CME Group
Nasdaq
Cboe
TradingView
Wall Street JournalNews
SESN
0.6288
0.00%
0.00
BUZZ-U.S. STOCKS ON THE MOVE-Venture Global, TSMC, Oracle
Reuters · 10/10 16:09
Carisma Therapeutics to Be Delisted from Nasdaq Will Trade on OTCID Amid Regulatory Noncompliance
Reuters · 10/09 21:12
Carisma Therapeutics Chief Scientific Officer Michael Klichinsky Reports Disposal of Common Shares
Reuters · 10/08 20:17
Carisma Therapeutics Chief Scientific Officer Michael Klichinsky Reports Disposal of Common Shares
Reuters · 10/03 21:25
Ocugen Inc. Announces Termination of Merger Agreement with Carisma Therapeutics Due to Funding Shortfall
Reuters · 09/18 15:01
Carisma Therapeutics Amends Agreement with Moderna, Receives $4 Million Payment
Reuters · 09/18 13:15
Ocugen Inc. Finalizes Merger Agreement with Carisma Therapeutics, Inc., Including a $5 Million Investment in Common Stock
Reuters · 09/05 20:12
Carisma Therapeutics Inc. Announces $5 Million Share Purchase Agreement with Ocugen in Private Placement
Reuters · 08/29 20:21
Carisma Therapeutics Inc. Held Special Stockholders Meeting
Reuters · 08/08 20:07
Carisma Therapeutics Inc. Faces Potential Delisting from Nasdaq Due to Non-Compliance with Listing Rules
Reuters · 07/15 20:16
CARISMA THERAPEUTICS INC - TO BE RENAMED ORTHOCELLIX AND TRADE UNDER TICKER OCLX
Reuters · 06/23 11:30
CARISMA THERAPEUTICS: TO ISSUE TO PRE-MERGER ORTHOCELLIX STOCKHOLDER SHARES OF CO'S COMMON STOCK AS MERGER CONSIDERATION
Reuters · 06/23 11:30
Based on the provided financial report articles, the title of the article is:
"Carisma Therapeutics Inc. (Form 10-K)
Press release · 04/07 12:05
Carisma Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Reuters · 03/31 23:04
CARISMA THERAPEUTICS INC: HAS PAUSED ALL RESEARCH AND DEVELOPMENT ACTIVITIES AT THIS TIME, PENDING OUTCOME OF REVIEW
Reuters · 03/31 20:30
CARISMA THERAPEUTICS INC: ON DEC 24, APPOINTS NATALIE MCANDREW AS PRINCIPAL FINANCIAL OFFICER
Reuters · 12/26/2024 21:04
CARISMA THERAPEUTICS INC <CARM.O>: BAIRD CUTS TO NEUTRAL RATING; CUTS TARGET PRICE TO $1 FROM $10
Reuters · 12/12/2024 06:13
CARISMA THERAPEUTICS INC <CARM.O>: BTIG CUTS TO NEUTRAL FROM BUY
Reuters · 12/10/2024 08:31
CARISMA THERAPEUTICS INC - CHIEF FINANCIAL OFFICER, RICHARD MORRIS WILL LEAVE COMPANY EFFECTIVE DEC 31
Reuters · 12/09/2024 13:30
CARISMA THERAPEUTICS, INC. <CARM.O>: H.C. WAINWRIGHT CUTS TARGET PRICE TO $5 FROM $8
Reuters · 11/25/2024 11:12
More
Webull provides a variety of real-time SESN stock news. You can receive the latest news about Sesen Bio, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About SESN
Carisma Therapeutics Inc., formerly Sesen Bio, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing immunotherapies for patients with cancer and other serious disorders. Its platform is focused on engineered macrophages, cells that plays a role in both the innate and adaptive immune response. Its pipeline includes multiple chimeric antigen receptor (CAR) macrophages designed to target solid tumors by engineering a patient’s own immune cells. Its technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and cellular therapy for the treatment of human disease. The Company's pipeline includes CT-0508, CT-0525, CT-1119 and CT-0729. Its CT-0508 and CT-0525 is an ex vivo gene-modified autologous CAR-Macrophage cellular therapy to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2) metastasis. Its CT-1119 is a ex vivo gene-modified autologous CAR-Macrophage cellular therapy.